Antidiarrheals, such as loperamide, are medications that help to stop or slow down passage of liquid or loose stool. Antidiarrheals have been suggested as a conservative measure for patients on immunotherapy experiencing low grade diarrhea. These agents are sometimes administered in combination with other immunotherapy-induced diarrhea treatments (i.e. steroids). Management strategies for immunotherapy-induced diarrhea are dependent on severity, associated symptoms, endoscopic, radiologic, and laboratory findings, and the exclusion of other causes (i.e., infection, neutropenic colitis) (Copeland et. al., 2023).

View Intervention Evaluation Table

Copeland, D., Dalton, K., Maupin, A., Peterson, K., & Weimer, J. (2023).  Gastrointestinal and mucosal toxicities. In M. Olsen, K. LeFebvre, S. Walker, & E. Prechtel Dunphy (Eds.), Chemotherapy and immunotherapy guidelines and recommendations for practice (2nd ed., pp.425-491). Oncology Nursing Society.